Skip to main content

Table 10 Laboratory adverse experiences occurring at an incidence rate of ≥1% in any group

From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

Adverse Experience Sitagliptin 100 mg
n/N (%)
Non-Exposed
n/N (%)
Difference between Sitagliptin
and Non-Exposed,
% (95% CI)*
Alanine Aminotransferase Increased 51/3365 (1.5) 37/2672 (1.4) 0.1 (-0.5, 0.7)
Aspartate Aminotransferase Increased 35/3365 (1.0) 26/2672 (1.0) 0.1 (-0.5, 0.6)
Blood Uric Acid Increased 37/3364 (1.1) 22/2672 (0.8) 0.3 (-0.2, 0.8)
Creatine Phosphokinase Increased 22/819 (2.7) 11/619 (1.8) 0.9 (-0.7, 2.5)
Creatinine Clearance Estimation Decreased 31/3243 (1.0) 14/2551 (0.5) 0.4 (-0.1, 0.9)
Fasting Blood Glucose Increased 52/3370 (1.5) 63/2675 (2.4) -0.8 (-1.6, 0.1)
Low Density Lipoprotein Increased 5/185 (2.7) 2/169 (1.2) 1.5 (-1.9, 5.1)
Protein Urine Present 19/1541 (1.2) 7/1209 (0.6) 0.7 (-0.1, 1.4)
Urine Microalbumin Present 2/228 (0.9) 9/251 (3.6) -2.7 (-5.9, 0.1)
  1. CI = confidence interval
  2. Data are number of patients with a laboratory adverse experience/number of patients with laboratory measurement expressed as a percentage (n/N [%]).
  3. *Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.